Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced Practice Perspective

The tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, nilotinib, bosutinib, and ponatinib have drastically improved the life expectancies of patients with chronic myeloid leukemia in chronic phase (CML-CP). While survival outcomes are comparable across first-line TKIs, each TKI has a unique tox...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Adv Pract Oncol
Hlavní autoři: Bauer, Stephanie, Comer, Holly, Ramsey, Brooke, Thomas, Katy
Médium: Artigo
Jazyk:Inglês
Vydáno: Harborside Press LLC 2021
Témata:
Grand Rounds
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8299797/
https://ncbi.nlm.nih.gov/pubmed/34430062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2021.12.5.7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky